Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 66 for “"Denosumab"”.
-
Η χρήση διφωσφονικών και denosumab στην οστική μεταστατική νόσο
… νόσο περιλαμβάνει τα διφωσφονικά και το denosumab, το οποίο είναι επίσης ένας ισχυρός αναστολέας των οστεοκλαστών. Η ευρεία χρήση αυτών των φαρμάκων μπορεί να μην έχει αυξήσει το προσδόκιμο, έχει όμως βελτιώσει σημαντικά την ποιότητα ζωής των ασθενών. Υπό μελέτη βρίσκεται η επίδραση των …
-
Η συγκριτική επίδραση της δενοσουμάβης και των διφωσφονικών στον οστικό μεταβολισμό ελληνίδων μετεμμηνοπαυσιακών γυναικών
Bisphosphonates and denosumab are two widely used antiresorptive agents for the treatment of postmenopausal osteoporosis. Aim of this retrospective follow- up study was to clarify any differences between these two pharmacological agents in terms of bone densitometry and bone metabolism laboratory …
-
A comprehensive study into the mineralization mechanisms of giant cell tumors of bone in the spine during denosumab treatment
… cells, triggering osteolysis. For over a decade, denosumab, a monoclonal antibody targeting this receptor activator, has been approved to facilitate surgical resection or in the setting of inoperable tumors. Although variable degrees of tumor mineralization have been observed in clinical …
-
RANKL inhibition in the amelioration of sarcopenia: potential cross-tissue effects of musculoskeletal therapies
Osteoprotegerin (OPG) and denosumab, a human monoclonal antibody, bind and inhibit RANKL, a major regulator of osteoclastic bone resorption. As well as reducing fracture risk, use of denosumab has also significantly reduced fall incidence in placebo-controlled trials, suggesting RANKL inhibition …
-
Σύγκριση της χορήγησης denosumab ως νεοεπικουρικής θεραπείας πριν την απόξεση, έναντι απόξεσης ως μονοθεραπείας, για την αντιμετώπιση του προχωρημένου (Campanacci III) γιγαντοκυτταρικού όγκου των οστών. Μια μετα-ανάλυση και συστηματική ανασκόπηση της βιβλιογραφίας
Εισαγωγή: Το denosumab είναι ένα μονοκλωνικό αντίσωμα που προσδένεται στον RANKL και έχει πάρει έγκριση για τη χρήση του στον προχωρημένο γιγαντοκυτταρικό όγκο των οστών. Η πιθανή επίδραση του φαρμάκου στον τοπικό έλεγχο της νόσου αλλά και η συσχέτιση του με την τοπική υποτροπή της νόσου δεν είναι …
-
Prevention of rebound bone loss following withdrawal of RANKL inhibition
Denosumab is a potent inhibitor of RANKL-mediated osteoclast formation and activity, increasing BMD and reducing fracture risk. This has revolutionised treatment of osteoporosis and other skeletal conditions where suppression of bone resorption is required. However, discontinuation leads to a …
-
Comparación del efecto de Denosumab con zoledronato en el metabolismo mineral óseo de pacientes afectas de osteoporosis : estudio con seguimiento a 3 años
… 5 mg i.v. 1 vez al año, con el tratamiento con denosumab, a dosis de 60 mg s.c. Cada 6 meses, sobre la densidad mineral ósea, en la columna lumbar y en la extremidad proxima l del fémur, en un período de 3 años. 2. Comparar en los mismos pacientes el efecto sobre el remodelado, estimando el …
-
Antimicrobial peptide gene expression in medication-related osteonecrosis of the jaw
Bisphosphonates and denosumab are commonly used antiresorptive therapies in patients with bone metastasis and osteoporosis. Medication-related osteonecrosis of the jaw (MRONJ) is a serious side effect of these drugs, and infection has been recognized as a contributing factor. Current therapeutic …
-
The effect of Denosumab, the inhibitor for receptor activator of nuclear factor kappa-B ligand (RANKL), on dinitrobenzensulfonic acid (DNBS)-induced experimental model of crohn's disease.
… study aims to elucidate if the RANKL inhibitor Denosumab (Prolia™) can reduce the severity of experimental colitis via modifying gut microbiota dysregulation. Methods: CD-like colitis was induced via intrarectal administration of dinitrobenzenesulfonic acid (DNBS, 4mg/kg) dissolved in Ethanol …
-
Μελέτη του ρόλου της πρωτεϊνης RANKL στον καρκίνο του μαστού και στην οστική μετάσταση σε διαγονιδιακά ποντίκια
… settings, we evaluated the efficacy of denosumab, a monoclonal antibody against huRANKL, in mammary cancer and bone metastasis models, as well as of the bisphosphonate zoledronic acid in bone metastasis. The overall approach of these experiments aims to clarify the role of RANKL in the …
-
Der Einfluss verschiedener Strategien der antiresorptiven Therapie auf den Zeitpunkt des Auftretens und den chirurgischen Therapieerfolg der Medikamenten-assoziierten Kiefernekrose
… patients treated with bisphosphonates (BP) or denosumab (DNO), and for patients who switched the antiresorptive drug (BP/DNO). Patients and Methods: A retrospective single-center cohort study with patients suffering from MRONJ was conducted. The predictor variable was the antiresorptive …
-
Investigation of the possibilities for host modulation therapy for periodontal treatment
… seeks to evaluate the feasibility of repurposing denosumab, a monoclonal antibody against RANKL used in osteoporosis, as a therapeutic adjunct in periodontitis. Methods: Two research questions were addressed. First, salivary concentrations of OPG, RANKL, and inflammatory cytokines (IL-1β, IL-6, …
-
Novel regulators and inhibitors of aortic valve calcification
… phosphate (Na3PO4), pH 7.4, and the effect of Denosumab (inhibitor of Receptor Activator of Nuclear factor K-B Ligand, RANKL) at a working concentration of 50μg/mL was analysed. mRNA expression of osteoblast and myofibroblast markers were measured by quantitative polymerase chain reaction …
-
Determinants of bone health in type 2 diabetes and Charcot neuropathic osteoarthropathy, and a step toward intervention
… of the Charcot Foot Quantitative Ultrasound and Denosumab Study (CRUSADES). This ambitious multicentre randomised controlled trial (RCT) monitors calcaneal QUS over 18-months with denosumab used as a novel therapeutic in acute CN. CRUSADES is the first Australian RCT in acute CN, and one of three …
Page 1 of 4